Market Research Industry Reports

EpiCast Report: Fragile X Syndrome - Epidemiology Forecast to 2026

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
EpiCast Report: Fragile X Syndrome - Epidemiology Forecast to 2026

Summary

Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability. FXS affects both men and women and the condition is also linked to other neurological and psychiatric disorders (CDC, 2017a). FXS is caused by an abnormal expansion in the number of the trinucleotide CGG repeats located in the 5 UTR in the fragile X mental retardation 1 gene (FMR1) at Xq27.3. Patients affected with FXS have more than 200 repeats of the CGG trinucleotide caused by full mutation of the FMR1 gene (NFXF, 2017; Saldarriaga et al., 2014).

In the 7MM, the diagnosed prevalent cases of FXS are expected to increase from 88,457 cases in 2016 to 91,919 cases in 2026, at an Annual Growth Rate (AGR) of 0.39% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the diagnosed prevalent cases of FXS will increase from 36,942 cases in 2016 to 37,767 cases in 2026, at an AGR of 0.22%. When examining the AGR by individual market, GlobalData forecasts that all markets will see an increase in the diagnosed prevalent cases of FXS during the forecast period except Germany and Japan, with AGRs of negative 0.22% and negative 0.31%, respectively, during the forecast period.

GlobalData epidemiologists developed the epidemiological forecast for the diagnosed prevalent cases of FXS segmented by age and sex in the 7MM. GlobalData epidemiologists used consistent methodology across the 7MM to ensure the comparability of the disease populations across the 7MM.

Scope

- The Fragile X Syndrome (FXS) EpiCast Report provides an overview of the risk factors and global trends of FXS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast of the diagnosed prevalent cases of FXS in these markets from 2016-2026. The prevalent cases are further segmented by age (0-19 years, 20-39 years, 40-59 years, 60-79 years, and 80 years and older) and sex.
- The FXS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The FXS EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global FXS market.
- Quantify patient populations in the global FXS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for FXS therapeutics in each of the markets covered.

2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 Related Reports 5
2.2 Upcoming Reports 5
3 Epidemiology 6
3.1 Disease Background 6
3.2 Risk Factors and Comorbidities 6
3.3 Global and Historical Trends 7
3.4 Forecast Methodology 8
3.4.1 Sources 8
3.4.2 Forecast Assumptions and Methods 8
3.5 Epidemiological Forecast for FXS (2016-2026) 9
3.5.1 Diagnosed Prevalent Cases of FXS 9
3.5.2 Age-Specific Diagnosed Prevalent Cases of FXS 10
3.5.3 Sex-Specific Diagnosed Prevalent Cases of FXS 11
3.6 Discussion 11
3.6.1 Epidemiological Forecast Insight 11
3.6.2 Limitations of Analysis 12
3.6.3 Strengths of Analysis 12
4 Appendix 13
4.1 Bibliography 13
4.2 About the Authors 14
4.2.1 Epidemiologist 14
4.2.2 Reviewers 14
4.2.3 Global Director of Therapy Analysis and Epidemiology 15
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 15
4.3 About GlobalData 16
4.4 Contact Us 16
4.5 Disclaimer 16

List Of Tables

1.1 List of Tables
Table 1: Comorbidities for FXS 7
Table 2: 7MM, Diagnosed Prevalent Cases of FXS, All Ages, Both Sexes, N, 2016-2026 9

List Of Figures

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of FXS, Both Sexes, All Ages, N, 2016 and 2026 5
Figure 2: 7MM, Sources Used, Diagnosed Prevalent Cases of FXS 8
Figure 3: 7MM, Age-Specific Diagnosed Prevalent Cases of FXS, Both Sexes, N, 2016 10
Figure 4: 7MM, Sex-Specific Diagnosed Prevalent Cases of FXS, All Ages, N, 2016 11

EpiCast Report: Painful Diabetic Neuropathy - Epidemiology Forecast to 2026

EpiCast Report: Painful Diabetic Neuropathy - Epidemiology Forecast to 2026Painful diabetic neuropathy (PDN) is a long-term complication of diabetes mellitus (DM). Over time, diabetic patients may develop this nerve disorder,

USD 3995View Report

EpiCast Report: Fragile X Syndrome - Epidemiology Forecast to 2026

EpiCast Report: Fragile X Syndrome - Epidemiology Forecast to 2026Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability. FXS affects both men and women and the

USD 3995View Report

EpiCast Report: Painful Diabetic Neuropathy - Epidemiology Forecast to 2026

EpiCast Report: Painful Diabetic Neuropathy - Epidemiology Forecast to 2026Painful diabetic neuropathy (PDN) is a long-term complication of diabetes mellitus (DM). Over time, diabetic patients may develop this nerve disorder,

USD 3995View Report

EpiCast Report: Glaucoma - Epidemiology Forecast to 2026

EpiCast Report: Glaucoma - Epidemiology Forecast to 2026Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eyes optic nerve, resulting in progressive, irreversible vision loss.

USD 3995View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 3995
  • Site Licence    USD 7990
  • Enterprise Wide Licence    USD 11985
$ 3995

Reports Details

Published Date : Jan 2018
No. of Pages :16
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube